Communiqués Matinas BioPharma Holdings, Inc.

Actions

MTNB

US5768103039

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:32:24 20/08/2026			Varia. 5j.	Varia. 1 janv.
0,1894 ^USD	-21,41%		-19,48%	-67,99%

13:39	Les plus fortes baisses en avant-Bourse	MT
13/08	Matinas BioPharma Holdings, Inc. publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2026	CI

Communiqués

30/07	GH Power and TKMS Continue to Explore Clean Energy Collaboration in Support of Canada’s Future Patrol Submarine Project	BU
13/07	GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma	BU
13/07	Matinas BioPharma : Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals	PU
13/07	Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals	AQ
26/06	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance	AQ
06/04	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards	AQ
03/04	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards	AQ
11/03/25	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors	AQ
13/02/25	Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors	AQ
07/02/25	Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair	AQ
10/01/25	Matinas BioPharma Receives NYSE Noncompliance Notice	AQ
27/11/24	Matinas BioPharma : Current Report Form 8 K	PU
14/11/24	Matinas BioPharma : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
31/10/24	Matinas BioPharma : Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction Form 8 K	PU
31/10/24	Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction	AQ
24/10/24	Matinas BioPharma : Current Report Form 8 K	PU
14/08/24	Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update	GL
07/08/24	Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024	GL
24/06/24	Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program	GL
13/06/24	Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin	GL
13/06/24	Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin	AQ
16/05/24	New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024	AQ
16/05/24	New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024	GL
09/05/24	Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update	GL
07/05/24	Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting	GL